LUMAKRAS Market

“LUMAKRAS Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about LUMAKRAS for Pancreatic Cancer in the seven major markets. A detailed picture of the LUMAKRAS for pancreatic cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the LUMAKRAS for pancreatic cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the LUMAKRAS market forecast analysis for pancreatic cancer in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in pancreatic cancer.

Drug Summary

Amgen’s Sotorasib (LUMAKRAS/AMG 510) is a small molecule that specifically and irreversibly inhibits KRASG12C through a unique interaction with the P2 pocket. The inhibitor traps KRASG12C in the inactive GDP-bound state by a mechanism similar to that described for other KRASG12C inhibitors.

The drug is already indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR).

Currently, the drug is being investigated in Phase I/II of clinical development for KRAS p.G12C mutant advanced solid tumors, including pancreatic cancer.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the LUMAKRAS description, mechanism of action, dosage and administration, research and development activities in pancreatic cancer.
• Elaborated details on LUMAKRAS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the LUMAKRAS research and development activities in pancreatic cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around LUMAKRAS.
• The report contains forecasted sales of for pancreatic cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for pancreatic cancer.
• The report also features the SWOT analysis with analyst views for LUMAKRAS in pancreatic cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

LUMAKRAS Analytical Perspective by DelveInsight

In-depth LUMAKRAS Market Assessment

This report provides a detailed market assessment of LUMAKRAS for pancreatic cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data of LUMAKRAS.

LUMAKRAS Clinical Assessment

The report provides the clinical trials information of LUMAKRAS for pancreatic cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for pancreatic cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence LUMAKRAS dominance.
• Other emerging products for pancreatic cancer are expected to give tough market competition to LUMAKRAS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of LUMAKRAS in pancreatic cancer.
• Our in-depth analysis of the forecasted sales data of LUMAKRAS will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the LUMAKRAS in pancreatic cancer.

Key Questions

• What is the product type, route of administration and mechanism of action of LUMAKRAS?
• What is the clinical trial status of the study related to LUMAKRAS in pancreatic cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the LUMAKRAS development?
• What are the key designations that have been granted to LUMAKRAS for pancreatic cancer?
• What is the forecasted market scenario of LUMAKRAS for pancreatic cancer?
• What are the forecasted sales of LUMAKRAS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to LUMAKRAS for pancreatic cancer?
• Which are the late-stage emerging therapies under development for the treatment of pancreatic cancer?